



# Emergency Medicine Research Office News

**Summer of 2020, Emergency Medicine Research Office (EMRO) as well as multiple investigators, site staff, organization and external organizations participated in the ACTT-2 Trial. Their hard work and data resulted in the May 11, 2022 announcement from Lilly that the US FDA gave full approval for baricitinib (OLUMIANT®) for the treatment of hospitalized patients with COVID-19.**

**See link below:**

**[FDA Approves Lilly and Incyte's OLUMIANT® \(baricitinib\) for the Treatment of Certain Hospitalized Patients with COVID-19 | Eli Lilly and Company](#)**

**A large part of the data supporting this approval was based on ACTT-2.**

**There are only two FDA approved drugs for treatment of COVID-19: remdesivir and baricitinib. ACTT played a critical role in each of these.**

**Congratulations to all!**